Protalix BioTherapeutics (PLX) Net Margin (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Net Margin of 54.48% for Q1 2026, up 9027.0% year-over-year from 0.6% in Q1 2025, and up 238.67% quarter-over-quarter from 39.29% in Q4 2025.
Protalix BioTherapeutics (PLX) Net Margin (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 54.48% for Q1 2026.
- In Q1 2026, Net Margin rose 9027.0% year-over-year to 54.48%; the TTM figure through Mar 2026 stood at 23.06% (up 891.0% YoY), while the FY2025 annual figure was 8.88%, down 2289.0% from the prior year.
- Net Margin for Q1 2026 stood at 54.48%, up from 39.29% in the prior quarter.
- The five-year high for Net Margin was 59.31% in Q4 2024, with the low at 191.91% in Q4 2023.
- The 5-year median for Net Margin is 17.9% (2023), against an average of 23.45%.
- The sharpest annual moves came in 2023 and 2024: Net Margin tumbled 15466 bps in 2023, then soared 25123 bps in 2024.
- Protalix BioTherapeutics' Net Margin stood at 37.25% in 2022, then plunged by 415 bps to 191.91% in 2023, then soared by 131 bps to 59.31% in 2024, then slumped by 166 bps to 39.29% in 2025, then soared by 239 bps to 54.48% in 2026.
- Business Quant data shows PLX's Net Margin at 54.48% in Q1 2026, 39.29% in Q4 2025, and 13.52% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Protalix BioTherapeutics | 192.37 Mn | 151.71 Mn | 12.13 Mn | 18.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.98% |
| Mar 31, 2026 | 54.48% |
| Dec 31, 2025 | -39.29% |
| Sep 30, 2025 | 13.52% |
| Jun 30, 2025 | 2.52% |
| Mar 31, 2025 | -35.79% |
| Dec 31, 2024 | 59.31% |
| Sep 30, 2024 | 19.33% |
| Jun 30, 2024 | -16.35% |
| Mar 31, 2024 | -122.60% |
| Dec 31, 2023 | -191.91% |
| Sep 30, 2023 | -17.90% |
| Jun 30, 2023 | 46.21% |
| Mar 31, 2023 | -32.66% |
| Dec 31, 2022 | -37.25% |
| Sep 30, 2022 | -25.15% |
| Jun 30, 2022 | -60.94% |
| Mar 31, 2022 | -14.21% |
| Dec 31, 2021 | -77.37% |
| Sep 30, 2021 | -35.63% |